Michael Schmitz
Stock Analyst at Guggenheim
(1.39)
# 2,944
Out of 4,479 analysts
12
Total ratings
63.64%
Success rate
2.58%
Average return
Main Sectors:
Top Industries:
6 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MRUS Merus | Maintains: Buy | $57 → $93 | $53.09 | +75.17% | 1 | May 28, 2024 | |
| ARVN Arvinas | Upgrades: Buy | $40 | $24.85 | +60.97% | 1 | Nov 20, 2023 | |
| RVMD Revolution Medicines | Reiterates: Buy | $38 | $37.38 | +1.66% | 1 | Feb 28, 2023 | |
| FATE Fate Therapeutics | Downgrades: Neutral | n/a | $3.22 | - | 1 | Jan 3, 2023 | |
| BPMC Blueprint Medicines | Maintains: Buy | $110 → $85 | $110.36 | -22.98% | 7 | Nov 2, 2022 | |
| NOVA Sunnova Energy International | Initiates: Buy | n/a | $5.17 | - | 1 | Jan 6, 2020 |
Merus
May 28, 2024
Maintains: Buy
Price Target: $57 → $93
Current: $53.09
Upside: +75.17%
Arvinas
Nov 20, 2023
Upgrades: Buy
Price Target: $40
Current: $24.85
Upside: +60.97%
Revolution Medicines
Feb 28, 2023
Reiterates: Buy
Price Target: $38
Current: $37.38
Upside: +1.66%
Fate Therapeutics
Jan 3, 2023
Downgrades: Neutral
Price Target: n/a
Current: $3.22
Upside: -
Blueprint Medicines
Nov 2, 2022
Maintains: Buy
Price Target: $110 → $85
Current: $110.36
Upside: -22.98%
Sunnova Energy International
Jan 6, 2020
Initiates: Buy
Price Target: n/a
Current: $5.17
Upside: -